Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma
Abstract Advanced natural killer/T cell lymphoma (NKTL) has demonstrated poor prognosis with currently available therapies. Here, we report the efficacy of anti-programmed death 1 (PD-1) antibody with the P-GEMOX (pegaspargase, gemcitabine, and oxaliplatin) regimen in advanced NKTL. Nine patients un...
Main Authors: | Jun Cai, Panpan Liu, Huiqiang Huang, Yajun Li, Shuyun Ma, Hui Zhou, Xiaopeng Tian, Yuchen Zhang, Yan Gao, Yi Xia, Xuanye Zhang, Hang Yang, Lirong Li, Qingqing Cai |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2020-12-01
|
Series: | Signal Transduction and Targeted Therapy |
Online Access: | https://doi.org/10.1038/s41392-020-00331-3 |
Similar Items
-
Body Composition as a Predictor of Toxicity and Prognosis in Patients with Diffuse Large B-Cell Lymphoma Receiving R-CHOP Immunochemotherapy
by: Jiaxun Guo, et al.
Published: (2021-03-01) -
Outcomes of patients treated with SVILE vs. P-GemOx for extranodal natural killer/T-cell lymphoma, nasal type: a prospective, randomized controlled study
by: Liqiang Wei, et al.
Published: (2020-08-01) -
ESHAP versus GEMOX in Management of Relapsed or Refractory Lymphoma: A Prospective Randomized Study
by: Hamdy Zawam, et al.
Published: (2018-06-01) -
Epstein-Barr Virus-Positive Natural Killer/T-Cell Lymphoma
by: Qingqing Cai, et al.
Published: (2019-05-01) -
Immunochemotherapy in experimental leishmaniasis
by: Eslami, Zohreh.
Published: (1996)